STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis CEO buys 98 shares in stock plan purchase

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC (IONS) reports that Chief Executive Officer and director Brett P. Monia acquired 98 shares of common stock on August 31, 2026 through the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this transaction, Monia directly holds 242,760 shares of Ionis common stock. According to the plan terms, these 98 shares may not be sold until February 28, 2027. No Rule 10b5-1 trading plan is reported for this transaction.

Positive

  • None.

Negative

  • None.
Insider Monia Brett P
Role Chief Executive Officer
Type Security Shares Price Value
Other Common Stock F1 98 $51.306 $5K
Holdings After Transaction: Common Stock — 242,760 shares (Direct)
Footnotes (1)
  1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Shares acquired 98 shares Common stock acquired on August 31, 2026 under the employee stock purchase plan
Purchase price per share $51.306 per share Price for the 98 shares acquired on August 31, 2026
Total direct holdings after transaction 242,760 shares Direct common stock holdings of Brett P. Monia after the August 31, 2026 acquisition
Share sale restriction end date February 28, 2027 Date after which the 98 acquired shares may be sold
Amended and Restated 2000 Employee Stock Purchase Plan financial
"Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan"
Common Stock financial
"security titled Common Stock acquired by Brett P. Monia"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Rule 10b5-1 trading plan regulatory
"No Rule 10b5-1 trading plan is reported for this transaction"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

What insider transaction did IONS report for Brett P. Monia on August 31, 2026?
On August 31, 2026, Brett P. Monia acquired 98 shares of Ionis Pharmaceuticals common stock at $51.306 per share through the company’s Amended and Restated 2000 Employee Stock Purchase Plan.

How many IONS shares does CEO Brett P. Monia hold after this Form 4 transaction?
After the reported transaction, Brett P. Monia directly holds 242,760 shares of Ionis Pharmaceuticals common stock, according to the Form 4 filing.

Was the August 31, 2026 IONS insider transaction part of a Rule 10b5-1 trading plan?
No. The Form 4 indicates that no Rule 10b5-1 plan applies to the August 31, 2026 transaction by Brett P. Monia.

Are the 98 IONS shares acquired by Brett P. Monia subject to any holding restrictions?
Yes. The footnote states the 98 shares purchased under the employee stock purchase plan on August 31, 2026 may not be sold until February 28, 2027.

What plan was used for Brett P. Monia’s August 31, 2026 purchase of IONS shares?
The 98 shares were purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan, as disclosed in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Monia Brett P
(Last)(First)(Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CALIFORNIA 92010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026J98(1)A$51.306242,760D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR